Prosecution Insights
Last updated: April 19, 2026
Application No. 18/256,680

A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN

Final Rejection §103§112
Filed
Jun 09, 2023
Examiner
SEAMAN, D MARGARET M
Art Unit
1625
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
The Scripps Research Institute
OA Round
2 (Final)
77%
Grant Probability
Favorable
3-4
OA Rounds
2y 4m
To Grant
84%
With Interview

Examiner Intelligence

Grants 77% — above average
77%
Career Allow Rate
1063 granted / 1387 resolved
+16.6% vs TC avg
Moderate +8% lift
Without
With
+7.9%
Interview Lift
resolved cases with interview
Typical timeline
2y 4m
Avg Prosecution
20 currently pending
Career history
1407
Total Applications
across all art units

Statute-Specific Performance

§101
3.7%
-36.3% vs TC avg
§103
15.1%
-24.9% vs TC avg
§102
24.3%
-15.7% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1387 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority This application was filed 06/09/2023 and is a 371 of PCT/US21/62538 (12/09/2021) which claims priority to PRO 63/124544 (12/11/2020). Claims 1-20 are before the Examiner. Claim Rejections - 35 USC § 112 The rejection of claim 20 under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends, as stated in paper dated 09/08/2025 has been overcome by applicant’s amendments and arguments in paper dated 12/03/2025. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The rejection of claims 1-20 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2011037929 and Zhang, as stated in paper dated 09/08/2025, is upheld. As previously stated, both references teach Pd(II) catalyzed hydroxlylation of arenes with O2 and a ligand. See pages 2-3 of the WO and Zhang. The rings that are hydroxylated are monocyclic or multiple cyclic rings. WO page 6 through first paragraph of page 7 teach that the rings can be heterocyclic or aromatic. WO teaches the preferred non-nucleophilic base (claim 18) is KOAc. The difference between the processes taught by the WO and Zhang and the instantly claimed process is the identity of the ligand of formula (L). Both Zhang and WO have tertiary amines present in the reaction just not the specified tertiary amine of claim 1. It would have been obvious to one of ordinary skill in the art at the time of the invention to use the same reaction taught by Zhang and the WO with a different tertiary amine with the reasonable expectation of getting the same reaction product. Rationale: It is within the skill of the ordinary artisan to choose a different tertiary amine (ligand) and use it as taught by the prior art with the expectation of getting the expected final reaction product. Applicant argues in paper dated 12/03/2025, that the palladium catalyst taught by the prior art is different from the instantly claimed catalyst. Claims 1-14 and 17-20, the catalyst claimed is “a source of Pd(II)”. Zhang teaches Pd(oAc)2 and ‘929 teaches Pd(oAc)2. These are both sources of Pd(II). Further, claim 15 is limited to “wherein the source of Pd(II) is a Pd(II) salt”. Claim 16 is further limited to “wherein the Pd(II) salt is at least one…of Pd(OAc)2,…PdCl2”. Both Zhang and ‘929 teach Pd(OAc)2 as the catalyst and ‘929 also teaches PdCl2. This is fully anticipatory of all the instant claims 1-20 including the limited claims 15 and 16. Applicants further argue that the tertiary amide of a carboxylic acid with oxygen in the presence of a Pd(II) catalyst (see claim 1 of ’929) is not sufficient of a teaching to equate to the instantly claimed Pd(II) in the presence of O2 and a ligand of formula (L) as claimed in the instant claim 1 is not sufficient teaching to obviate the instant L in the instant process. However, the instant process uses tertiary amines as a ligand (L) to make compounds of formula (2) from compound of formula (1). However, the prior art Zhang and ‘929 both teach the making of compound of (2) from (1) with a source of Pd(II) in the presence of O2 and a ligand. The same reactants making the same products in the same conditions. The only difference being the choice of ligands. This rejection is upheld. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to D MARGARET M SEAMAN whose telephone number is (571)272-0694. The examiner can normally be reached M-F 8am-4pm Eastern. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Andrew Kosar can be reached at 571-272-0913. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /D MARGARET M SEAMAN/Primary Examiner, Art Unit 1625
Read full office action

Prosecution Timeline

Jun 09, 2023
Application Filed
Sep 04, 2025
Non-Final Rejection — §103, §112
Dec 03, 2025
Response Filed
Dec 22, 2025
Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599135
A COMPOSITION AND METHOD FOR PREPARING N-PHENYLPYRAZOLE-1-CARBOXAMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12595234
Bioactive Benzocycloheptene Analogues From Himachalenes and its Applications
2y 5m to grant Granted Apr 07, 2026
Patent 12595239
SUBSTITUTED ISOXAZOLINE DERIVATIVES
2y 5m to grant Granted Apr 07, 2026
Patent 12590072
THYROMIMETICS
2y 5m to grant Granted Mar 31, 2026
Patent 12577207
INDAZOLE DERIVATIVES AS CANNABINOID RECEPTOR PARTIAL AGONISTS
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
77%
Grant Probability
84%
With Interview (+7.9%)
2y 4m
Median Time to Grant
Moderate
PTA Risk
Based on 1387 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month